Zacks Maintains Strong $4.44 Price Target for Pressure BioSciences Inc. (PBIO)

• Zacks has reiterated support for their initial $4.44 share price target for Pressure BioSciences
• PBIO’s fundamentals remain strong, with record sales of consumables and increased revenue from products and services over same quarter previous year
• Company anticipates doubling of total revenue in 2020, driven by anticipated sales of their proprietary BaroShear K45 System, which provides the CBD market with much-needed, superior water-soluble nanoemulsions of CBD Oil

Zacks Small Cap Research, a division of Zacks Investment Research, has announced that they are maintaining their strong $4.44 share price target originally stated in their initial coverage of Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the sale and development of pressure-based consumables, instruments, and platform technology solutions to the global life sciences industry. PBIO’S unique and enabling pressure platform technologies can be used in many large and growing markets (e.g., food preservation, medical/lab applications, and, importantly, CBD oil water solubility).

The Zacks report (http://ibn.fm/z1W3H) points to demand that “is expected to accelerate starting in 2020,” which nonetheless follows many years of consistent yearly revenue increases by PBIO. The company itself is standing by its stated anticipation of doubling revenue in 2020, due to expected sales of their soon-to-be-released $200,000 BaroShear K45 systems. These new instrument systems utilize PBI’s proprietary Ultra Shear Technology™ (UST) platform to effectively produce high quality, long-term stable, water-soluble nanoemulsions of CBD Oil (http://ibn.fm/PFora).

True water-soluble CBD is now seen as critical to the CBD market, since water-solubility is necessary for bioavailability. It also allows for accurate dosing for consumers, something that has been sorely missing up to now. Without accurate dosing, you can’t really control the amount of CBD that actually gets into the bloodstream and available by the consumer. In essence, it doesn’t matter how organic or potent a company says their CBD is, if it is not truly water soluble then it is not going to be properly absorbed by the body and will be largely excreted. PBIO’s revolutionary, patented, and highly anticipated UST-based BaroShear K45 system is expected to provide superior water-solubility, long-term shelf stability, improved safety, and significantly increased bio-availability compared to current nanoemulsification methods, overcoming key weaknesses of the other approaches.

The BaroShear K45 features a unique, highly efficient, customized ultra-high pressure (UHP) subsystem generating pressure levels of up to 45,000 psi. The system’s maximum throughput capacity is one liter per eight hours. The platform is also suitable for processing small volumes (e. g., min. 20 ml) of high-quality CBD oil into a water-soluble nanoemulsion with minimal production loss.

To view the full Zacks report, visit http://ibn.fm/z1W3H

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php